RU2020120797A - Пептидные композиции - Google Patents

Пептидные композиции Download PDF

Info

Publication number
RU2020120797A
RU2020120797A RU2020120797A RU2020120797A RU2020120797A RU 2020120797 A RU2020120797 A RU 2020120797A RU 2020120797 A RU2020120797 A RU 2020120797A RU 2020120797 A RU2020120797 A RU 2020120797A RU 2020120797 A RU2020120797 A RU 2020120797A
Authority
RU
Russia
Prior art keywords
optionally substituted
polypeptide according
amino acid
denotes
pharmaceutically acceptable
Prior art date
Application number
RU2020120797A
Other languages
English (en)
Russian (ru)
Inventor
Шубх ШАРМА
Леонардус Х.Т. ВАН ДЕР ПЛУГ
Барт ХЕНДЕРСОН
Original Assignee
Ритм Фармасьютикалз, Инк.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ритм Фармасьютикалз, Инк. filed Critical Ритм Фармасьютикалз, Инк.
Publication of RU2020120797A publication Critical patent/RU2020120797A/ru

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/665—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans derived from pro-opiomelanocortin, pro-enkephalin or pro-dynorphin
    • C07K14/68—Melanocyte-stimulating hormone [MSH]
    • C07K14/685—Alpha-melanotropin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/50—Cyclic peptides containing at least one abnormal peptide link
    • C07K7/54—Cyclic peptides containing at least one abnormal peptide link with at least one abnormal peptide link in the ring
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
    • A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/12—Drugs for genital or sexual disorders; Contraceptives for climacteric disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/06—Antihyperlipidemics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Endocrinology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Diabetes (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Reproductive Health (AREA)
  • Toxicology (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Emergency Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Gynecology & Obstetrics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
RU2020120797A 2013-03-15 2014-03-14 Пептидные композиции RU2020120797A (ru)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361790469P 2013-03-15 2013-03-15
US61/790,469 2013-03-15

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
RU2015145593A Division RU2725150C2 (ru) 2013-03-15 2014-03-14 Пептидные композиции

Publications (1)

Publication Number Publication Date
RU2020120797A true RU2020120797A (ru) 2020-07-02

Family

ID=50588892

Family Applications (2)

Application Number Title Priority Date Filing Date
RU2020120797A RU2020120797A (ru) 2013-03-15 2014-03-14 Пептидные композиции
RU2015145593A RU2725150C2 (ru) 2013-03-15 2014-03-14 Пептидные композиции

Family Applications After (1)

Application Number Title Priority Date Filing Date
RU2015145593A RU2725150C2 (ru) 2013-03-15 2014-03-14 Пептидные композиции

Country Status (10)

Country Link
US (4) US10196425B2 (cg-RX-API-DMAC7.html)
EP (2) EP2970388B1 (cg-RX-API-DMAC7.html)
JP (4) JP6622690B2 (cg-RX-API-DMAC7.html)
CN (3) CN105492456B (cg-RX-API-DMAC7.html)
AU (5) AU2014227712B2 (cg-RX-API-DMAC7.html)
CA (1) CA2906694A1 (cg-RX-API-DMAC7.html)
ES (1) ES2693761T3 (cg-RX-API-DMAC7.html)
RU (2) RU2020120797A (cg-RX-API-DMAC7.html)
TR (1) TR201815173T4 (cg-RX-API-DMAC7.html)
WO (1) WO2014144260A1 (cg-RX-API-DMAC7.html)

Families Citing this family (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT3539551T (pt) 2011-12-29 2021-11-04 Rhythm Pharmaceuticals Inc Método de tratamento de distúrbios associados ao recetor de melanocortina-4 em portadores heterozigóticos
CA3209602A1 (en) 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
WO2016168388A2 (en) 2015-04-14 2016-10-20 Palatin Technologies, Inc. Therapies for obesity, diabetes and related indications
AU2016330773A1 (en) * 2015-09-30 2018-04-19 Charité-Universitätsmedizin Berlin Method of treating melanocortin-4 receptor pathway-associated disorders
CN109803979B (zh) * 2016-10-04 2023-01-31 帝斯曼知识产权资产管理有限公司 黑皮质素-1-受体激动剂
CN111032680A (zh) * 2017-03-15 2020-04-17 诺和诺德股份有限公司 能够与黑皮质素4受体结合的双环化合物
WO2019195756A1 (en) 2018-04-06 2019-10-10 Rhythm Pharmaceuticals, Inc. Compositions for treating kidney disease
WO2020053414A1 (en) * 2018-09-14 2020-03-19 Novo Nordisk A/S Bicyclic compounds capable of acting as melanocortin 4 receptor agonists
CA3192873A1 (en) * 2020-09-24 2022-03-31 Leonardus H.T. Van Der Ploeg Methods of treating melanocortin-4 receptor pathway-associated disorders
CN113332416B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备治疗非酒精性脂肪肝药物中的应用
CN113209270B (zh) * 2021-05-17 2022-02-22 宁波大学 丙谷二肽在制备防治急性肝衰竭药物中的应用
CN116789802A (zh) * 2023-06-25 2023-09-22 湖北省农业科学院畜牧兽医研究所 一种山羊mc4r增强型突变体及其应用
WO2025131101A1 (zh) * 2023-12-22 2025-06-26 上海多米瑞生物技术有限公司 多肽化合物、其药物组合物及其用途

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0292291B1 (en) * 1987-05-22 1994-08-10 University Patents, Inc. Linear and cyclic analogs of alpha-msh fragments with extraordinary potency
US5731408A (en) * 1995-04-10 1998-03-24 Arizona Board Of Regents On Behalf Of The University Of Arizona Peptides having potent antagonist and agonist bioactivities at melanocortin receptors
GB9827500D0 (en) * 1998-12-14 1999-02-10 Wapharm Ab Compounds for control of eating, growth and body weight
US7176279B2 (en) * 2000-06-28 2007-02-13 Palatin Technologies, Inc. Cyclic peptide compositions and methods for treatment of sexual dysfunction
WO2003006620A2 (en) * 2001-07-11 2003-01-23 Palatin Technologies, Inc. Linear and cyclic melanocortin receptor-specific peptides
MXPA03001721A (es) * 2000-08-30 2003-05-27 Hoffmann La Roche Peptidos ciclicos selectivos.
US7342089B2 (en) * 2001-07-11 2008-03-11 Palatin Technologies, Inc. Cyclic peptides for treatment for cachexia
US7345144B2 (en) * 2001-07-11 2008-03-18 Palatin Technologies, Inc. Cyclic peptides for treatment of cachexia
US7034004B2 (en) * 2002-05-07 2006-04-25 University Of Florida Peptides and methods for the control of obesity
FR2851563B1 (fr) 2003-02-26 2005-04-22 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
FR2852957B1 (fr) 2003-03-31 2005-06-10 Sod Conseils Rech Applic Nouveaux derives d'imidazo-pyridine et leur utilisation en tant que medicament
US20060293223A1 (en) * 2003-06-19 2006-12-28 Eli Lilly And Company Patent Division Uses of melanocortin-3 receptor (mc3r) agonist peptides
EP1644023A2 (en) * 2003-06-19 2006-04-12 Eli Lilly And Company Melanocortin recptor 4(mc4) agonists and their uses
FR2862971B1 (fr) 2003-11-28 2006-03-24 Sod Conseils Rech Applic Nouveaux derives de benzimidazole et d'imidazo-pyridine et leur utilisation en tant que medicament
US8343031B2 (en) * 2004-03-23 2013-01-01 Michael Gertner Obesity treatment systems
FR2872165B1 (fr) 2004-06-24 2006-09-22 Sod Conseils Rech Applic Nouveaux derives de pyrimido-benzimidazole
CN101528250A (zh) 2005-07-08 2009-09-09 研究及应用科学协会股份有限公司 黑皮质素受体的配体
CN105837661B (zh) * 2005-07-08 2024-10-15 益普生制药股份有限公司 黑皮质素受体配体
EP2148692B1 (en) * 2007-05-25 2017-01-25 Ipsen Pharma S.A.S. Melanocortin receptor ligands modified with hydantoin
US20100173834A1 (en) 2007-06-15 2010-07-08 Zheng Xin Dong Cyclic peptide melanocortin receptor ligands
RU2453328C2 (ru) 2007-11-05 2012-06-20 Ипсен Фарма С.А.С. Применение меланокортинов для лечения чувствительности к инсулину
WO2009151383A1 (en) * 2008-06-09 2009-12-17 Palatin Technologies, Inc. Melanocortin receptor-specific peptides for the treatment of obesity and other diseases associated with melanocortin receptor function
NZ596617A (en) * 2009-06-08 2014-04-30 Palatin Technologies Inc Melanocortin receptor-specific peptides
UY32690A (es) * 2009-06-08 2011-01-31 Astrazeneca Ab Péptidos específicos para receptores de melanocortina
EP2461681A4 (en) * 2009-08-05 2013-04-24 Ipsen Pharma Sas USE OF MELANOCORTINS FOR TREATING DYSLIPIDEMIA
US20120226018A1 (en) 2009-11-16 2012-09-06 Ipsen Pharma, S.A.S. Process for the Synthesis of Ac-Arg-Cyclo(Cys-D-Ala-His-D-Phe-Arg-Trp-Cys)-NH2
ES2654147T3 (es) 2009-11-16 2018-02-12 Ipsen Pharma S.A.S. Composiciones farmacéuticas de ligandos del receptor de melanocortina
EP2720684B1 (en) 2011-06-14 2019-01-16 Ipsen Pharma S.A.S. A sustained-release composition containing peptides as the active ingredient
EP2705835A1 (en) 2012-06-08 2014-03-12 Ipsen Pharma S.A.S. Aqueous gelling compositions of soluble active pharmaceutical peptides providing modified release
RU2020120797A (ru) * 2013-03-15 2020-07-02 Ритм Фармасьютикалз, Инк. Пептидные композиции
CA3209602A1 (en) * 2013-03-15 2014-09-18 Rhythm Pharmaceuticals, Inc. Pharmaceutical compositions

Also Published As

Publication number Publication date
ES2693761T3 (es) 2018-12-13
WO2014144260A1 (en) 2014-09-18
CN118240012A (zh) 2024-06-25
US20160017001A1 (en) 2016-01-21
JP2025102830A (ja) 2025-07-08
EP3450449A2 (en) 2019-03-06
RU2725150C2 (ru) 2020-06-30
AU2024200528A1 (en) 2024-02-15
JP2019172693A (ja) 2019-10-10
US20250188124A1 (en) 2025-06-12
AU2018256493A1 (en) 2018-11-22
JP6622690B2 (ja) 2019-12-18
HK1220697A1 (en) 2017-05-12
TR201815173T4 (tr) 2018-11-21
CN105492456B (zh) 2024-11-01
US12077612B2 (en) 2024-09-03
EP2970388B1 (en) 2018-07-25
US10196425B2 (en) 2019-02-05
US20210040155A1 (en) 2021-02-11
AU2014227712B2 (en) 2018-08-02
CA2906694A1 (en) 2014-09-18
US20190092815A1 (en) 2019-03-28
AU2020203353A1 (en) 2020-06-11
AU2021269411A1 (en) 2021-12-16
CN105492456A (zh) 2016-04-13
EP3450449A3 (en) 2019-06-12
JP2016516719A (ja) 2016-06-09
EP2970388A1 (en) 2016-01-20
AU2014227712A1 (en) 2015-10-01
US10858399B2 (en) 2020-12-08
JP2022084844A (ja) 2022-06-07
CN118271400A (zh) 2024-07-02
JP7654587B2 (ja) 2025-04-01
JP7046871B2 (ja) 2022-04-04
RU2015145593A (ru) 2017-04-24

Similar Documents

Publication Publication Date Title
RU2020120797A (ru) Пептидные композиции
CA2777758C (en) Peptidic glp-2 agonists
JP2016516719A5 (cg-RX-API-DMAC7.html)
TWI666026B (zh) Ｗｔ１抗原胜肽結合疫苗
ES2544573T3 (es) Inhibidores diméricos de afinidad elevada de PSD-95 y su uso para el tratamiento del daño cerebral isquémico y del dolor
RU2013154047A (ru) Пептидные лекарственные препараты с повышенной эффективностью против инсулинорезистентности
JP2014507402A5 (cg-RX-API-DMAC7.html)
JP2013518115A5 (cg-RX-API-DMAC7.html)
JP2009532385A5 (cg-RX-API-DMAC7.html)
RU2014101697A (ru) Коагонисты рецепторов глюкагона/glp-1
RU2017105115A (ru) Пептидные ингибиторы рецептора интерлейкина-23 для перорального приема и их применение для лечения воспалительных заболеваний кишечника
JP2012530145A5 (cg-RX-API-DMAC7.html)
JP2015532283A5 (cg-RX-API-DMAC7.html)
KR20220035199A (ko) 인크레틴 유사체의 제조 방법
US20200165300A1 (en) Cyclic Peptides Targeting Alpha-4-Beta-7 Integrin
US10471136B2 (en) Pharmaceutical composition for injection
JPWO2014142102A1 (ja) 液体水性組成物
AU2004232314B2 (en) Peptide vectors
RU2015103816A (ru) ПРОНИКАЮЩИЕ В КЛЕТКУ ПЕПТИДЫ, МИШЕНЬЮ КОТОРЫХ ЯВЛЯЕТСЯ eIF4E
RS54722B1 (sr) Agonisti v1a receptora
JP2017527538A5 (cg-RX-API-DMAC7.html)
RU2013102588A (ru) Новые октапептидные соединения и их терапевтическое применение
RU2019119378A (ru) Антагонисты grpr для обнаружения, диагностики и лечения grpr-позитивного онкологического заболевания
NZ761754B2 (en) Acylated oxyntomodulin peptide analog
BR112015024583B1 (pt) Composto, suas composições e seu uso para a produção de um medicamento para o tratamento de câncer